Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

NCT07481747 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

2539

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities

Interventions

DRUG: Tirzepatide
DRUG: Placebo
BEHAVIORAL: Reduced-calorie diet

Sponsor

Hudson Biotech